| First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer L Horn, AS Mansfield, A Szczęsna, L Havel, M Krzakowski, MJ Hochmair, ... New England Journal of Medicine 379 (23), 2220-2229, 2018 | 2715 | 2018 |
| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The Lancet Oncology 21 (2), 271-282, 2020 | 1355 | 2020 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1) A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017 | 772 | 2017 |
| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 647 | 2020 |
| Pembrolizumab for platinum-and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study J Bauml, TY Seiwert, DG Pfister, F Worden, SV Liu, J Gilbert, NF Saba, ... Journal of Clinical Oncology 35 (14), 1542, 2017 | 644 | 2017 |
| Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133) SV Liu, M Reck, AS Mansfield, T Mok, A Scherpereel, N Reinmuth, ... Journal of Clinical Oncology 39 (6), 619-630, 2021 | 418 | 2021 |
| Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study G Giaccone, C Kim, J Thompson, C McGuire, B Kallakury, JJ Chahine, ... The Lancet Oncology 19 (3), 347-355, 2018 | 342 | 2018 |
| Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ... The lancet oncology 22 (7), 959-969, 2021 | 314 | 2021 |
| What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC) A Drilon, G Li, S Dogan, M Gounder, R Shen, M Arcila, L Wang, ... Annals of Oncology 27 (5), 920-926, 2016 | 309 | 2016 |
| Refining the treatment of NSCLC according to histological and molecular subtypes A Thomas, SV Liu, DS Subramaniam, G Giaccone Nature reviews Clinical oncology 12 (9), 511-526, 2015 | 309 | 2015 |
| Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer AF Farago, LP Le, Z Zheng, A Muzikansky, A Drilon, M Patel, TM Bauer, ... Journal of Thoracic Oncology 10 (12), 1670-1674, 2015 | 231 | 2015 |
| Neoadjuvant therapy for breast cancer SV Liu, L Melstrom, K Yao, CA Russell, SF Sener Journal of surgical oncology 101 (4), 283-291, 2010 | 225 | 2010 |
| Detection of NRG1 gene fusions in solid tumors S Jonna, RA Feldman, J Swensen, Z Gatalica, WM Korn, H Borghaei, ... Clinical Cancer Research 25 (16), 4966-4972, 2019 | 181 | 2019 |
| Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study RB Cohen, JP Delord, T Doi, SA Piha-Paul, SV Liu, J Gilbert, AP Algazi, ... American journal of clinical oncology 41 (11), 1083-1088, 2018 | 171 | 2018 |
| Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer JJ Lin, SV Liu, CE McCoach, VW Zhu, AC Tan, S Yoda, J Peterson, A Do, ... Annals of Oncology 31 (12), 1725-1733, 2020 | 166 | 2020 |
| COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials A Desai, JF Gainor, A Hegde, AM Schram, G Curigliano, S Pal, SV Liu, ... Nature reviews Clinical oncology 18 (5), 313-319, 2021 | 151 | 2021 |
| Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial AS Mansfield, A Każarnowicz, N Karaseva, A Sánchez, R De Boer, ... Annals of oncology 31 (2), 310-317, 2020 | 139 | 2020 |
| Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer … A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019 | 131 | 2019 |
| Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor–refractory differentiated thyroid cancer: results of a multicenter phase II International Thyroid … ME Cabanillas, JA De Souza, S Geyer, LJ Wirth, ME Menefee, SV Liu, ... Journal of Clinical Oncology 35 (29), 3315, 2017 | 119 | 2017 |
| Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection NJ Shah, G Al-Shbool, M Blackburn, M Cook, A Belouali, SV Liu, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 111 | 2019 |
